Edition:
United States

Biocartis Group NV (BCART.BR)

BCART.BR on Brussels Stock Exchange

11.41EUR
15 Dec 2017
Change (% chg)

€0.12 (+1.02%)
Prev Close
€11.30
Open
€11.65
Day's High
€11.70
Day's Low
€11.32
Volume
203,522
Avg. Vol
112,834
52-wk High
€14.08
52-wk Low
€9.40

Select another date:

Mon, Dec 4 2017

BRIEF-Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests

* BIOCARTIS AND AMGEN SIGN COMPANION DIAGNOSTIC AGREEMENT FOR IDYLLA(TM) RAS BIOMARKER TESTS

BRIEF-Biocartis Raises 80 Million Dollars

* ANNOUNCED ON TUESDAY THAT IT RAISED EUR 80 MILLION IN GROSS PROCEEDS

BRIEF-Bookrunner says Biocartis Group deal upsized to 80 mln euros From 60 mln euros base deal size‍​

* BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS DEAL UPSIZED TO 80 MILLION EUROS FROM 60 MILLION EUROS BASE DEAL SIZE‍​

BRIEF-Biocartis Share Offering Of Up To About 8.9 mln Shares ‍​- bookrunner

* SAYS OFFERING DEAL SIZE ABOUT 60 MILLION EUROS‍​ Further company coverage:

BRIEF-Biocartis Launches Equity Placement

* REG-BIOCARTIS GROUP NV: BIOCARTIS LAUNCHES EQUITY PLACEMENT

BRIEF-Biocartis Group Launches Liquid Biopsy Tests with Merck

* ‍TESTS DEVELOPED UNDER PARTNERSHIP WITH MERCK KGAA, DARMSTADT, GERMANY​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biocartis Group sees ‍2017 guidance reiterated

* ‍CASH POSITION AT END OF Q3 2017 AMOUNTED TO APPROXIMATELY EUR 56 MILLION (UNAUDITED FIGURE)​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Genomic Health and Biocartis announce agreement to develop a breast cancer test

* ‍GENOMIC HEALTH AND BIOCARTIS ANNOUNCE AGREEMENT TO DEVELOP AN IDYLLA(TM) IVD ONCOTYPE DX(®) BREAST CANCER TEST TO BROADEN GLOBAL PATIENT ACCESS​

BRIEF-Biocartis H1 total operating income up at 6.8 million euros

* H1 TOTAL OPERATING INCOME EUR 7.0 MILLION VERSUS EUR 6.8 MILLION YEAR AGO

BRIEF-Biocartis' Idylla respiratory panel receives clearance by FDA

* REG-BIOCARTIS GROUP NV: IDYLLA(TM) RESPIRATORY (IFV-RSV) PANEL RECEIVES 510(K) CLEARANCE BY US FDA Source text: http://bit.ly/2vGWUK1 Further company coverage: (Gdynia Newsroom)

Select another date: